LINC01505: A Drug Target / Disease Biomarker (G100996590)

Target Name: LINC01505

NCBI ID: G100996590

LINC01505

Other Name(s): long intergenic non-protein coding RNA 1505 | Long intergenic non-protein coding RNA 1505

LINC01505: A Drug Target / Disease Biomarker

LINC01505 is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a key regulator of cell growth and differentiation, and has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the most promising aspects of LINC01505 is its potential as a drug target. LINC01505 has been shown to interact with a wide range of molecules, including transcription factors, signaling proteins, and cellular signaling pathways. This makes it an attractive target for researchers to study and potentially develop as a new drug.

One of the key challenges in studying LINC01505 as a drug target is its complex structure. LINC01505 is a protein that consists of multiple domains, including an N-terminus, a T-terminus, and a middle body that contains multiple 伪-helices. These domains give LINC01505 a highly complex structure, which can be difficult to study and understand.

To study LINC01505 at the protein level, researchers have used a variety of techniques, including biochemical assays, mass spectrometry, and imaging techniques. These techniques have allowed researchers to understand the structure and function of LINC01505, as well as its potential interactions with other molecules.

One of the key insights that researchers have gained from studying LINC01505 is its role in cell signaling. LINC01505 has been shown to play a key role in regulating cell growth and differentiation, as well as in controlling the movement of cells along the body's longest axis, the spine. This makes LINC01505 an attractive target for drugs that are designed to promote or inhibit cell signaling.

Another promising aspect of LINC01505 is its potential as a therapeutic target for neurodegenerative diseases. LINC01505 has been shown to interact with a variety of neurotransmitters, including dopamine, a chemical that is involved in the transmission of signals in the brain. This makes LINC01505 a potential target for drugs that are designed to modulate dopamine signaling in the brain.

In addition to its potential as a drug target, LINC01505 also has a number of potential applications in basic research. For example, studies of LINC01505 have shown that it plays a key role in regulating the development and maintenance of tissues, as well as in controlling the structure and function of individual cells. This has led to a better understanding of the underlying mechanisms that govern these processes, and has implications for the study of a wide range of diseases.

Overall, LINC01505 is a protein that has a wide range of potential applications, both as a drug target and as a tool for basic research. With further study, researchers may be able to fully understand its role in the regulation of cell growth and differentiation, and use this knowledge to develop new treatments for a variety of diseases.

Protein Name: Long Intergenic Non-protein Coding RNA 1505

The "LINC01505 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01505 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets